Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study

PloS One
Elie AzoulayM Wolff

Abstract

To demonstrate the feasibility and safety of weekly high-dose liposomal amphotericin B (L-AmB) (as a pre-emptive antifungal treatment) for 2 weeks in patients with septic shock and Candida colonization. Pilot, multicentre, open-label, prospective study conducted in seven French ICUs. Non-immunocompromised patients, receiving mechanical ventilation were eligible if they presented ICU-acquired severe sepsis requiring newly administered antibacterial agents and Candida colonization in at least two sites. Exclusion criteria included the need for antifungal therapy and creatinine > 220 μmol/L. All patients were to receive a high-dose L-AmB (10 mg/kg/week) for two weeks. A follow-up period of 21 days following the second administration of L-AmB was conducted. Treated patients were compared to 69 matched untreated controls admitted in the same ICUs before the study period. Twenty-one patients were included in the study, of which 20 received at least one infusion of high-dose L-AmB. A total of 24 adverse events were identified in 13(61%) patients. Fourteen adverse events were categorized as serious in 8(38%) patients. In four cases the adverse events were considered as potentially related to study drug administration and resulted in L-...Continue Reading

References

Dec 22, 1993·JAMA : the Journal of the American Medical Association·J R Le GallF Saulnier
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A M RentzR Bowden
Jul 18, 2000·Antimicrobial Agents and Chemotherapy·T J WalshL Zech
Apr 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H Rex, J D Sobel
Feb 22, 2003·Surgical Infections·R K PelzC W Hendrix
Sep 19, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Juster-ReicherE Leibovitz
Nov 1, 2003·The Lancet Infectious Diseases·Philippe EggimannDidier Pittet
Mar 1, 2006·Critical Care Medicine·Luis Ostrosky-Zeichner, Peter G Pappas
May 2, 2006·International Journal of Antimicrobial Agents·Anna Maria TortoranoRenee Grillot
May 10, 2006·Mycoses·Kevin W GareyDimitrios P Kontoyiannis
Mar 3, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L Ostrosky-ZeichnerJ H Rex
Apr 20, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Oliver A CornelyUNKNOWN AmBiLoad Trial Study Group
Jul 16, 2008·Annals of Internal Medicine·Mindy G SchusterJohn H Rex
Mar 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine CordonnierMichaël Schwarzinger
Dec 21, 2010·Critical Care Medicine·Daniel H KettUNKNOWN Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators
Oct 8, 2011·The Journal of Antimicrobial Chemotherapy·Pierre FournierHervé Pelloux
Oct 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Koert RitmeijerRobert N Davidson
Oct 25, 2011·Critical Care : the Official Journal of the Critical Care Forum·Brunella PosteraroMassimo Antonelli
Jan 20, 2012·Emerging Infectious Diseases·Eric DannaouiUNKNOWN French Mycoses Study Group
Mar 15, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Barbara D AlexanderMichael A Pfaller
Feb 20, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-ZeichnerPeter G Pappas
May 9, 2014·Intensive Care Medicine·Matteo BassettiMario Tumbarello
Jun 18, 2014·Intensive Care Medicine·Philippe Eggimann, Didier Pittet
Aug 6, 2014·Intensive Care Medicine·Danièle MaubonMuriel Cornet
Aug 7, 2014·Intensive Care Medicine·Olivier LortholaryUNKNOWN French Mycosis Study Group
Sep 1, 2015·The Journal of Antimicrobial Chemotherapy·F LanternierUNKNOWN French Mycosis Study Group

❮ Previous
Next ❯

Citations

Feb 13, 2020·Revista Da Sociedade Brasileira De Medicina Tropical·Leticia Aparecida SchiaveRoberto Martinez
Feb 5, 2021·Expert Opinion on Pharmacotherapy·Liliana ScorzoniEleftherios Mylonakis

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.